Rykowski J J, Hilgier M
Anaesthesia Department, Ludvika Hospital, Sweden.
Anesthesiology. 2000 Feb;92(2):347-54. doi: 10.1097/00000542-200002000-00014.
Neurolytic celiac plexus block (NCPB) is an effective way of treating severe pain in some patients with pancreatic malignancy. However, there are no studies to date that evaluate the effectiveness of NCPB related to the site of primary pancreas cancer. The aim of the study was to assess the effectiveness of NCPB in pancreatic cancer pain, depending on the location of the pancreatic tumor.
The prospective study was conducted in 50 consecutive patients diagnosed with pancreatic cancer. The patients were categorized into two different groups depending on tumor localization: group 1: patients with the cancer of the head of the pancreas and group 2: patients with the cancer of the body and tail of the pancreas. The qualitative and quantitative pain analyses were performed before and after NCPB. The patients underwent prognostic celiac plexus block with bupivacaine, followed by neurolysis during fluoroscopic control within the next 24 h.
After NCPB, 37 patients (74%) had effective pain relief during the first 3 months or until death. Of the 37 patients who had effective pain relief, 33 (92%) were from group 1 and 4 (29%) were from group 2. In the remaining 13 patients (3 patients from group 1 and 10 patients from group 2), pain relief after NCPB was not satisfactory. Those patients were scheduled for repeated retrocrural neurolysis during computed tomography control. Computed tomography showed massive growth of the tumor around the celiac axis with metastases. After repeated neurolysis, pain relief clinically still was not satisfactory, necessitating additional opioid treatment.
In this study, unilateral transcrural celiac plexus neurolysis has been shown to provide effective pain relief in 74% of patients with pancreatic cancer pain. Neurolysis was more effective in cases with tumor involving the head of the pancreas. In the cases with advanced tumor proliferation, regardless of the technique used, the analgesic effects of NCPB were not satisfactory.
腹腔神经丛阻滞术(NCPB)是治疗某些胰腺癌患者重度疼痛的有效方法。然而,迄今为止尚无研究评估与原发性胰腺癌部位相关的NCPB有效性。本研究的目的是根据胰腺肿瘤的位置评估NCPB对胰腺癌疼痛的有效性。
对50例连续诊断为胰腺癌的患者进行前瞻性研究。根据肿瘤定位将患者分为两个不同组:第1组:胰头癌患者;第2组:胰体尾癌患者。在NCPB前后进行定性和定量疼痛分析。患者先接受布比卡因预后性腹腔神经丛阻滞,随后在接下来的24小时内于透视控制下进行神经松解。
NCPB后,37例患者(74%)在最初3个月或直至死亡期间疼痛得到有效缓解。在37例疼痛得到有效缓解的患者中,33例(92%)来自第1组,4例(29%)来自第2组。其余13例患者(第1组3例,第2组10例)NCPB后的疼痛缓解不令人满意。这些患者计划在计算机断层扫描控制下进行重复的膈脚后神经松解。计算机断层扫描显示腹腔干周围肿瘤大量生长并伴有转移。重复神经松解后,临床疼痛缓解仍不令人满意,需要额外的阿片类药物治疗。
在本研究中,单侧经皮腹腔神经丛神经松解术已被证明可使74%的胰腺癌疼痛患者获得有效的疼痛缓解。神经松解术在肿瘤累及胰头的病例中更有效。在肿瘤晚期增殖的病例中,无论使用何种技术,NCPB的镇痛效果均不令人满意。